loader2
Login Open ICICI 3-in-1 Account

Akums Drugs & Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Akums Drugs & Pharmaceuticals Ltd. 08 Aug 2025 18:02 PM

Q1FY26 Quarterly Result Announced for Akums Drugs & Pharmaceuticals Ltd.

Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q1FY26 results

  • Total income: Rs 1,051 crore compared to Rs 1,026 crore during Q1FY25,
  • EBITDA: Rs 156 crore compared to Rs 111 crore during Q1FY25,
  • EBITDA Margin: 14.8% for Q1FY26.
  • PAT: Rs 65 crore compared to Rs 44 crore during Q1FY25,
  • PAT Margin: 6.2% for Q1FY26.

Sanjeev Jain, Managing Director, said: " This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor. "

Sandeep Jain, Managing Director, said: "We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead. "

Result PDF

Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Akums reported revenue of Rs 1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth.
  • The company posted a 10.4% EBITDA margin with Adj EBITDA of 111 crore
  • Adj PAT stood at Rs 44 crore for Q4FY25 compared to Rs 46 crore for Q4FY24

FY25 Financial Highlights:

  • Akums closed FY25 with consolidated total income of Rs 4,170 crore
  • An adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year with Adj EBITDA of 513 crore..
  • Adj PAT stood at Rs 234 crore for FY25 compared to Rs 220 crore for FY24

Commenting on the results, Sanjeev Jain, Managing Director, said: " As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums’ global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies."

Sandeep Jain, Managing Director, added: "It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals—operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization."

Result PDF

Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q3FY25 results

  • Total Income at Rs 10,250 million, decline of 6.1% YoY, decline of 2.1% QoQ.
  • Adjusted EBITDA of Rs 1,359 million, up 12.1% YoY, up 0.9% QoQ.
  • Adj EBITDA Margin at 13.3%, Adj PAT Margin at 6.5%.
  • Adjusted PAT of Rs 663 million, up 15.2% YoY, decline of 0.5% QoQ.

Sanjeev Jain, Managing Director, said: “Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a EUR 200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.”

Sandeep Jain, Managing Director, said: “We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.”

Result PDF

Pharmaceuticals company Akums Drugs & Pharmaceuticals announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Adjusted PAT of Rs 667 million,up 16.2% QoQ, up by 8.9% YOY.
  • Adj EBITDA Margin at 12.9%; Adj PAT Margin at 6.4%.
  • Total Income at Rs 10,466 million,Growth of 2.0% QoQ, down of 11.9% YoY.
  • Adjusted EBITDA of Rs 1,347 million,up 3.0% QoQ, down 28.0% YoY

H1FY25 Financial Highlights:

  • Adjusted PAT of Rs 1,240 million, up by 25.4%.
  • Adj EBITDA Margin at 12.8%; Adj PAT Margin at 6.0%.
  • Total Income at Rs 20,722 million, down of 4.3% YoY.
  • Adjusted EBITDA of Rs 2,654 million, down 10.1% YoY.
  • Cash surplus at Rs 3,406 million.

Sanjeev Jain, Managing Director, said: “Short term volatility apart, we continue to see strong secular demand for outsourced drug development and manufacturing. We will continue to invest in building world-class capabilities to help our clients launch new formulations and therapies, and drive their growth. The company is taking long term measures to further strengthen its leadership position in the CDMO space.”

“Our focus continues to be on the development of innovative products and platforms, exploring more markets towards our larger objective of driving profitable growth. Q2 business performance reflects the muted volume demand and low API prices. We remain committed to our long term vision of being a global CDMO player”.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app